YQA14

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 561748

CAS#: 1221408-42-9

Description: YQA14 is a selective D3 receptor antagonist.

Chemical Structure

img
YQA14
CAS# 1221408-42-9
Instruction

Theoretical Analysis

MedKoo Cat#: 561748
Name: YQA14
CAS#: 1221408-42-9
Chemical Formula: C23H27ClN4O3
Exact Mass: 442.18
Molecular Weight: 442.940
Elemental Analysis: C, 62.37; H, 6.14; Cl, 8.00; N, 12.65; O, 10.84

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: YQA14; YQA-14; YQA 14;

IUPAC/Chemical Name: N-[4-[4-(5-Chloro-2-methylphenyl)-1-piperazinyl]butyl]-2,3-dihydro-2-oxo-5-benzoxazolecarboxamide

InChi Key: VIZDBZXBKIEXRK-UHFFFAOYSA-N

InChi Code: InChI=1S/C23H27ClN4O3/c1-16-4-6-18(24)15-20(16)28-12-10-27(11-13-28)9-3-2-8-25-22(29)17-5-7-21-19(14-17)26-23(30)31-21/h4-7,14-15H,2-3,8-13H2,1H3,(H,25,29)(H,26,30)

SMILES Code: O=C(C1=CC=C(OC(N2)=O)C2=C1)NCCCCN3CCN(C4=CC(Cl)=CC=C4C)CC3

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 442.94 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Sun L, Song R, Chen Y, Yang RF, Wu N, Su RB, Li J. A selective D3 receptor antagonist YQA14 attenuates methamphetamine-induced behavioral sensitization and conditioned place preference in mice. Acta Pharmacol Sin. 2016 Feb;37(2):157-65. doi: 10.1038/aps.2015.96. Epub 2015 Dec 21. PubMed PMID: 26687935; PubMed Central PMCID: PMC4753378.

2: Liu F, Wang X, Li Z, Li J, Zhuang X, Zhang Z. P-Glycoprotein (ABCB1) limits the brain distribution of YQA-14, a novel dopamine D3 receptor antagonist. Chem Pharm Bull (Tokyo). 2015;63(7):512-8. doi: 10.1248/cpb.c15-00089. PubMed PMID: 26133067.

3: Chen Y, Song R, Yang RF, Wu N, Li J. A novel dopamine D3 receptor antagonist YQA14 inhibits methamphetamine self-administration and relapse to drug-seeking behaviour in rats. Eur J Pharmacol. 2014 Nov 15;743:126-32. doi: 10.1016/j.ejphar.2014.09.026. Epub 2014 Sep 26. PubMed PMID: 25261038.

4: Liu F, Zhuang X, Yang C, Li Z, Xiong S, Zhang Z, Li J, Lu C, Zhang Z. Characterization of preclinical in vitro and in vivo ADME properties and prediction of human PK using a physiologically based pharmacokinetic model for YQA-14, a new dopamine D3 receptor antagonist candidate for treatment of drug addiction. Biopharm Drug Dispos. 2014 Jul;35(5):296-307. doi: 10.1002/bdd.1897. Epub 2014 Apr 13. PubMed PMID: 24647883.

5: Hu R, Song R, Yang R, Su R, Li J. The dopamine D(3) receptor antagonist YQA14 that inhibits the expression and drug-primed reactivation of morphine-induced conditioned place preference in rats. Eur J Pharmacol. 2013 Oct 24. pii: S0014-2999(13)00782-6. doi: 10.1016/j.ejphar.2013.10.026. [Epub ahead of print] PubMed PMID: 24513519.

6: Hu R, Song R, Yang R, Su R, Li J. The dopamine D(3) receptor antagonist YQA14 that inhibits the expression and drug-prime reactivation of morphine-induced conditioned place preference in rats. Eur J Pharmacol. 2013 Nov 15;720(1-3):212-7. PubMed PMID: 24436985.

7: Song R, Bi GH, Zhang HY, Yang RF, Gardner EL, Li J, Xi ZX. Blockade of D3 receptors by YQA14 inhibits cocaine's rewarding effects and relapse to drug-seeking behavior in rats. Neuropharmacology. 2014 Feb;77:398-405. doi: 10.1016/j.neuropharm.2013.10.010. Epub 2013 Oct 28. PubMed PMID: 24176392; PubMed Central PMCID: PMC3867233.

8: Song R, Zhang HY, Peng XQ, Su RB, Yang RF, Li J, Xi ZX, Gardner EL. Dopamine D(3) receptor deletion or blockade attenuates cocaine-induced conditioned place preference in mice. Neuropharmacology. 2013 Sep;72:82-7. doi: 10.1016/j.neuropharm.2013.04.042. Epub 2013 May 2. PubMed PMID: 23643749; PubMed Central PMCID: PMC3742042.

9: Song R, Yang RF, Wu N, Su RB, Li J, Peng XQ, Li X, Gaál J, Xi ZX, Gardner EL. YQA14: a novel dopamine D3 receptor antagonist that inhibits cocaine self-administration in rats and mice, but not in D3 receptor-knockout mice. Addict Biol. 2012 Mar;17(2):259-73. doi: 10.1111/j.1369-1600.2011.00317.x. Epub 2011 Apr 20. PubMed PMID: 21507153; PubMed Central PMCID: PMC5531447.